Health & Fitness – The Manhica Health Research Center (CISM) Friday announced the promising malaria vaccine RTS,S/AS02D will undergo its third and final trials in mid-2008. CISM researcher Pedro Aide said, "The results of the second phase of vaccine trials, which have just come to an end, showed its capacity to reduce new infections in children by 65 percent.&qu
Not a member? Sign-up today!
About Propeller | Frequently Asked Questions | Help
© 2003-2008 Propeller. All Rights Reserved. Terms of Use | Privacy Policy
0)
Vote